pH‐selective mutagenesis of protein–protein interfaces: In silico design of therapeutic antibodies with prolonged half‐life

pH‐selective mutagenesis of protein–protein interfaces: In silico design of therapeutic antibodies with prolonged half‐life

Source :

• Proteins: Structure, Function, and Bioinformatics [ 0887-3585 ] ; 2013-04.

English descriptors

• Teeft :
  • Aevdw bmgel, Affinity, Alanine, Alanine scanning, Alanine scanning results, Backbone interactions, Binding, Binding affinity, Binding behavior, Binding energy, Binding interface, Binding partners, Binding profile, Binding profiles, Biol, Biol chem, Blue bars, Cancer cells, Charmm, Chem, Combinatorial problem, Comput chem, Computational, Computational protocol, Conformation, Conformational flexibility, Cumulative effect, Dielectric constants, Different solution, Discovery studio, Dmgmut, Electrostatic contribution, Electrostatic contributions, Electrostatic energy terms, Electrostatic interactions, Electrostatic term, Energy terms, Experimental data, Fcrn, Fractional protonation, Free energy, Free energy differences, Free energy terms, Full agreement, Good agreement, Histidine scanning, Homology, Homology model, Hotspot, Information table, Interface, Interface residues, Ionization, Ionization properties, Ligand binding, Lysosomal degradation, Mgel, Monoclonal antibodies, More mutations, Multiple protonation states, Murine, Murine fcrn, Mutagenesis, Mutant, Mutant structures, Mutation, Mutation energies, Mutation energy, Neonatal, Neonatal receptor, Neutral effect, Other hand, Other mutations, Phys chem, Possible states, Protein, Protein binding affinity, Protein complexes, Protein design, Protein engineering, Protein ionization, Protein stability, Protein therapeutics, Proton binding, Protonation, Protonation state, Receptor, Residue, Same approach, Scanning, Several types, Significant effect, Silico, Silico design, Silico predictions, Single mutations, Single protonation state, Spassov, Target antigen, Telesis court, Therapeutic antibodies, Titratable groups, Titratable residues, Titratible residues, Triple mutation, Turkey ovomucoid, Unbound, Unbound states, Wild type, Wiley periodicals.

Abstract

• https://api.istex.fr/ark:/67375/WNG-3S5BJ1LM-S/fulltext.pdf

Affiliations:

• États-Unis
• Californie

Links toward previous steps (curation, corpus...)

• to stream Istex, to step Corpus: 001254
• to stream Istex, to step Curation: 001254
• to stream Istex, to step Checkpoint: 000379
• to stream Main, to step Merge: 002902
• to stream Main, to step Curation: 002888

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002888 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002888 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:F35069162051402058E01877F9B59C7DF97FCD84
   |texte=   pH‐selective mutagenesis of protein–protein interfaces: In silico design of therapeutic antibodies with prolonged half‐life
}}

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021